Jay Bhattacharya is now at the pinnacle of American public health. As director of the National Institutes of Health, he already oversees the country’s biomedical research agenda. Now, as acting director of the Centers for Disease Control and Prevention, he also temporarily controls the nation’s disease surveillance and response mechanisms. The unusual consolidation of power has sparked unease among former officials and public health experts, who warn that the arrangement could undermine leadership at a moment of institutional instability.The Capitol Hill report first detailed these concerns.what happenedThe CDC’s top job has been in limbo for months. President Donald Trump’s original nominee, former Florida Rep. David Weldon, failed to gain enough support in the Senate. Susan Monarez, a longtime federal scientist who served as interim director and was later nominated permanently, was ousted. Health and Human Services Deputy Secretary Jim O’Neill then took over interim control.Bhattacharya is now the third acting CDC director in seven months while continuing to serve at the National Institutes of Health (NIH).In an internal email to CDC staff, he outlined three principles for the agency under his leadership: transparently updating guidance as new data emerges, ensuring investigations reflect accountability to the communities they serve, and strengthening internal review processes to increase accountability and openness.Why former officials are worriedThe NIH and CDC are not interchangeable institutions. NIH primarily funds and coordinates biomedical research. The CDC leads disease prevention, surveillance, outbreak response, and public health guidance.Former CDC doctor Elizabeth Souda told The Hill that it would be difficult for even the most experienced leaders to effectively manage both agencies at the same time. Others echoed the same concerns, arguing that each organization needs to have a different leadership focus.James Alwine, professor emeritus of cancer biology at the University of Pennsylvania and a member of the Volunteer Network Defending Public Health, said the missions and business needs are too different for one person to handle at the same time.In addition to workload, critics also point to Bhattacharya’s public image during the Covid-19 pandemic. A Stanford University physician and health economist, he rose to prominence as the co-author of the Great Barrington Declaration, which criticized widespread lockdowns. Supporters see him as a champion of open debate. Critics see him as skeptical of mainstream public health orthodoxy. That history makes his expanded powers particularly sensitive.wider contextThe unrest comes amid a broader reorganization of federal health agencies by the Trump administration. Leadership changes, policy reversals, and ideological tensions unsettle career scientists.This is not only about administrative efficiency, but also about credibility. CDC guidance influences global health policy. NIH manages billions of dollars in research funding and sets scientific priorities for universities and laboratories around the world.Public health emergencies do not pause for a change in bureaucracy. Whether this dual arrangement is stable or unstable will depend on how long it lasts and how effectively the two institutions operate under unified leadership.Currently, health agencies in Washington are watching closely. In public health, structure often determines substance. When two pillars of a system are placed under one roof, anxiety is inevitable, even if temporary.
